Skip to main content
Top
Published in: BMC Nephrology 1/2023

Open Access 01-12-2023 | Hypercalcemia | Case Report

Steroid responsive idiopathic calcitriol induced hypercalcemia: a case report and review of the literature

Authors: Omar El Fadel, Anshel Kenkare, Jingjing Zhang

Published in: BMC Nephrology | Issue 1/2023

Login to get access

Abstract

Background

Idiopathic Calcitriol Induced Hypercalcemia is a rare cause of a common condition of hypercalcemia. Hypercalcemia is most commonly the result of hyperparathyroidism and together with hypercalcemia of malignancy accounts for over 95% of cases. Idiopathic Calcitriol Induced Hypercalcemia can mimic hypercalcemia secondary to granulomatous diseases like sarcoidosis, but with apparent absences of both imaging and physical exam findings consistent with the disease. We report here a 51-year-old man who presented with recurrent nephrolithiasis, hypercalcemia, and acute kidney injury.

Case presentation

A 51-year-old man presented with severe back pain and mild hematuria. He had a history of recurrent nephrolithiasis over the course of a 15-year period. On presentation his calcium was elevated at 13.4 mg/dL, creatinine was 3.1 mg/dL (from baseline of 1.2), and his PTH was reduced at 5 pg/mL. CT abdomen and pelvis showed acute nephrolithiasis which was managed medically. Work up for the hypercalcemia included an SPEP which was normal, Vit D,1,25 (OH)2 was elevated at 80.4 pg/mL, CT chest showed no evidence of sarcoidosis. Management with 10 mg prednisone showed marked improvement in the hypercalcemia and he no longer had any symptoms of hypercalcemia.

Conclusion

Idiopathic Calcitriol Induced Hypercalcemia is a rare cause of hypercalcemia. All reported cases benefit from more intensive long-term immunosuppression. This report helps consolidate the diagnosis of Idiopathic Calcitriol Induced Hypercalcemia and encourages researchers to better investigate its underlying pathogenesis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kreisberg RA. Clinical problem-solving. Stopping short of certainty. N Engl J Med. 1994;331(1):42–5.CrossRefPubMed Kreisberg RA. Clinical problem-solving. Stopping short of certainty. N Engl J Med. 1994;331(1):42–5.CrossRefPubMed
2.
go back to reference Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6(5):442–7.CrossRefPubMed Sharma OP. Hypercalcemia in granulomatous disorders: a clinical review. Curr Opin Pulm Med. 2000;6(5):442–7.CrossRefPubMed
4.
go back to reference Kozeny GA, Barbato AL, Bansal VK, Vertuno LL, Hano JE. Hypercalcemia associated with silicone-induced granulomas. N Engl J Med. 1984;311(17):1103–5.CrossRefPubMed Kozeny GA, Barbato AL, Bansal VK, Vertuno LL, Hano JE. Hypercalcemia associated with silicone-induced granulomas. N Engl J Med. 1984;311(17):1103–5.CrossRefPubMed
5.
go back to reference Solling ASK, Tougaard BG, Harslof T, Langdahl B, Brockstedt HK, Byg KE, et al. Non-parathyroid hypercalcemia associated with paraffin oil injection in 12 younger male bodybuilders: a case series. Eur J Endocrinol. 2018;178(6):K29–K37.CrossRefPubMed Solling ASK, Tougaard BG, Harslof T, Langdahl B, Brockstedt HK, Byg KE, et al. Non-parathyroid hypercalcemia associated with paraffin oil injection in 12 younger male bodybuilders: a case series. Eur J Endocrinol. 2018;178(6):K29–K37.CrossRefPubMed
6.
go back to reference Evron E, Goland S, von der Walde J, Schattner A, Sthoeger ZM. Idiopathic calcitriol-induced hypercalcemia. A new disease entity? Arch Intern Med. 1997;157(18):2142–5.CrossRefPubMed Evron E, Goland S, von der Walde J, Schattner A, Sthoeger ZM. Idiopathic calcitriol-induced hypercalcemia. A new disease entity? Arch Intern Med. 1997;157(18):2142–5.CrossRefPubMed
7.
go back to reference Rijckborst V, van Wijngaarden P. Idiopathic calcitriol-induced hypercalcemia. Eur J Intern Med. 2008;19(8):e105–6.CrossRefPubMed Rijckborst V, van Wijngaarden P. Idiopathic calcitriol-induced hypercalcemia. Eur J Intern Med. 2008;19(8):e105–6.CrossRefPubMed
8.
go back to reference Komatsu BELMLMDEE. Calcitriol. Treasure Island (FL): StatPearls Publishing; 2022. Komatsu BELMLMDEE. Calcitriol. Treasure Island (FL): StatPearls Publishing; 2022.
9.
go back to reference David Feldman JWPaJSA. Vitamin D. PhilipSambrook, editor2011. David Feldman JWPaJSA. Vitamin D. PhilipSambrook, editor2011.
10.
go back to reference Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.CrossRefPubMedPubMedCentral Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.CrossRefPubMedPubMedCentral
11.
go back to reference Yasir MGA, Sonthalia S. Corticosteroid adverse Effects: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Yasir MGA, Sonthalia S. Corticosteroid adverse Effects: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022.
12.
go back to reference Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol. 2006;21(2):281–5.CrossRefPubMed Moudgil A, Przygodzki RM, Kher KK. Successful steroid-sparing treatment of renal limited sarcoidosis with mycophenolate mofetil. Pediatr Nephrol. 2006;21(2):281–5.CrossRefPubMed
Metadata
Title
Steroid responsive idiopathic calcitriol induced hypercalcemia: a case report and review of the literature
Authors
Omar El Fadel
Anshel Kenkare
Jingjing Zhang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2023
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-023-03203-4

Other articles of this Issue 1/2023

BMC Nephrology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine